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PMDIS
AN UNBIASED METHOD OF PHARMACEUTICAL
COST ANALYSIS
Nichol G, Wells G, Pham B
University of Ottawa, Ottawa, Canada
Pharmacoeconomic evaluation can assess costs by using
controlled trials. Statistical analysis of costs follows a
normal (N), lognormal (LN), or survival (S) model. Each
model assumes different statistical properties that may in-
troduce bias. If one pharmaceutical is less expensive and
more effective than another, then no incremental cost-
effectiveness ratio is calculated. Therefore, economically
attractive pharmaceuticals may not be identified if a bi-
ased method of cost analysis is used.
OBJECTIVE: The purpose of this study was to (1) evalu-
ate potential bias in methods of cost analysis and (2)
demonstrate an unbiased method.
METHODS: Cost models were considered unbiased if
they accounted for (l) independent variables, (2) disease-
specific death, (3) unrelated death (4) dropouts, and (5)
informative censoring. Potential differences in statistical
significance were demonstrated by simulating 12-month
cost data from the GUSTO study that compared use of
streptokinase and tissue plasminogen activator (TPA).
We simulated n = 10,000 from a gamma distribution for
each therapy, and 5% incidences of death, unrelated
death, or dropouts.
RESULTS: Nand LN only account for independent vari-
ables. Kaplan-Meier (KM) does not account for indepen-
dent variables, but competing risk (CR) accounts for all
factors. For streptokinase and TPA, mean actual costs
were $24,575 and $24,990; mean simulated costs were
$24,575 and $24,990. Costs of streptokinase versus TPA
were significantly different under N (mean difference
[95% confidence interval) = $415 [277-554), p <
0.001), and under LN ($431 [289-547), p < 0.001) For S
models, costs were not significantly different under KM
(hazard ratio for costs [95% confidence interval) = 0.94
[0.89-1.01), p = 0.08), or CR (0.96 [0.91-1.01), p =
0.09). The robustness of results and goodness of fit de-
pend upon the actual distribution of costs.
CONCLUSION: A competing risk model is an unbiased
and comprehensive method of cost analysis. Further re-
search is required to assess the clinical importance of al-
ternate methods of cost analysis.
PMDI.
IMPLICATION OF PREVENTING DISEASE ON
LIFE YEARS GAINED (LYG)
Caro JJ, Klittich WS, for the WOSCOPS Economic Analysis
Committee
Caro Research, Boston, MA, USA
While prevention of disease may lead to increased sur-
vival, appropriate estimation of LYG from shorter-term
clinical trials has been controversial, with some arguing
that only the gain actually observed during the trial is
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correct. The disagreement arises from a misunderstand-
ing of the methods used.
OBJECTIVE: To examine this misunderstanding using
the estimation of LYG by preventing cardiovascular dis-
ease (CVD) with pravastatin in hypercholesterolemic sub-
jects without pre-existing disease, based on the West of
Scotland Coronary Prevention Study.
METHODS: In WOSCOPS, there were 29 additional
survivors among treated patients accumulating 71.05
years during the trial. But what happens at the end of
the trial? Should one assume they all die immediately? A
more reasonable presumption is that they attain their
age and gender appropriate life expectancy. Although
hypercholesterolemic, they have been successfully treated,
and other trial selection criteria imply that they tend to
be healthier than their peers. A more difficult issue con-
cerns the non-fatal events prevented. Assigning no gain
in life expectancy to the 76 additional survivors in the
pravastatin group who remained free of cardiovascular
disease (CVD) is tantamount to dismissing the impact of
CVD on survival-a clinically untenable position. In-
stead, we estimated it using data from the Scottish
Record Linkage System on 460,000 residents who had
suffered a first CVD.
CONCLUSION: As LYG has become the predominant
denominator in cost-effectiveness ratios, their proper esti-
mation is crucial. Over- or under-estimation can lead to
erroneous conclusions by decision makers about the eco-
nomic efficiency of therapeutic interventions.
PMDI7
SURVEILLANCE OF A NEW DRUG IN THE
UNITED KINGDOM
Hartz SCI, West S2, Bunten E'
Medical Research Intemational, I Burlington. MA, USAand
2London, England, UK
Reports of adverse events often surface shortly after a
new drug is introduced and in many cases provoke gov-
ernmental regulatory action. Deaths pose a particular
challenge, because drug takers may have excess mortality
risk relative to nontakers for reasons unrelated to drug
use. Aside from the implications for safety surveillance, a
spurious association between drug use and mortality also
can confound economic comparisons based on drug use.
OBJECTIVE: To investigate, at the request of the U.K.
Medicines Control Agency, safety and health-care re-
source utilization related to use of a new drug.
METHODS: A postmarketing surveillance program was
implemented at major medical schools in England and
Scotland to monitor mortality, morbidity, and health-
care resource utilization associated with use of a new
drug for treating gastrointestinal conditions. The study
employs a longitudinal design that identified 18,000 drug
takers through automated pharmacy listings at 700+
general practitioner offices located within a one-hour
drive from the medical schools. In addition to drug taking
patterns and adverse event occurrences, use of arnbula-
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tory and hospital health-care resources is recorded. In-
stead of employing a reference group of nontakers, na-
tional death rates will serve as "historical controls."
RESULTS: Morbidity and mortality experience among
drug takers will be assessed by reviewing whether inci-
dents occurred concomitantly with use of the medicine,
by examining relationships with dose and duration of
use, and other evidence to establish "biologic plausibil-
ity." These experiences will be related in turn to selected
measures of health-care resource utilization.
CONCLUSION: This study provides a useful template
for future research to establish the safety and health care
resource utilization profiles of a new drug.
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